Details

NameSymbolSector
CONCORD DRUGS LIMITEDCONCORDPharmaceuticals
Open
69.18
High
69.39
Low
69
Close
69.39
Volume
9987
Exchange
bse
Time
03-Oct-2025

Outlook

Score:  

1

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Concord Drugs is  
Short Body
Estimated Stoploss of Concord Drugs is ₹  
69
Concord Drugs has a  
Bullishℹ
 pattern. 
Formation of  
Short Body
 candle pattern indicates the trend direction of Concord Drugs is  
Unpredictableℹ
. 

Trend

Concord Drugs is in  
Sideways trendℹ
. 
Price of Concord Drugs is  
Upℹ
 by  

11.04

%. 
Target
Buy @ 

48.48

Sell @ 

72.86

Current @ 

69.39

Volume

The trade volumes of Concord Drugs have become  
Deficientℹ
Though the volume trend for Concord Drugs appears  
Bullishℹ
 the participants seem to be  
Weak Buyersℹ
The trade volume of Concord Drugs is  

Down

 by  

23.06

% 

Valuation

The current market price of Concord Drugs is  
Overvaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 65cr and total assets worth ₹ 65cr, the balance sheet of Concord Drugs is:  
Balancedℹ
. 
Cashflow
Concord Drugs has  
Insufficientℹ
 cash flow because it is  

₹ 0cr

. It is  
Downℹ
 by  

0

%. 

(*Mar 2025)

50% i.e. ₹ 3cr earned in operatingℹ
33.33% i.e. ₹ 2cr spent in investingℹ
16.67% i.e. ₹ 1cr spent in financingℹ
0% in otherℹ
Concord Drugs has  
Insufficientℹ
 cash flow because it is  

₹ 0cr

. It is  
Downℹ
 by  

0

%. 

(*Mar 2024)

0% in operatingℹ
100% i.e. ₹ 1cr spent in investingℹ
0% in financingℹ
0% in otherℹ
Income
The income of Concord Drugs is  

₹ 13cr

 and  

Loss

 is :  

₹ 0cr

(*Jun 2025)

Concord Drugs Losses increased by:  

0

% and Income is Up by:  

30

% 

(*Jun 2025)

The income of Concord Drugs is  

₹ 10cr

 and  

Loss

 is :  

₹ 0cr

(*Mar 2025)

Concord Drugs Losses increased by:  

0

% and Income is Up by:  

0

% 

(*Mar 2025)

The income of Concord Drugs is  

₹ 10cr

 and  

Loss

 is :  

₹ 0cr

(*Dec 2024)

Concord Drugs Losses increased by:  

0

% and Income is Down by:  

16.67

% 

(*Dec 2024)

By using this site you agree to the use of cookies to deliver a better site experience.